亚洲日本一区二区三区在线播放-国产一区二区色淫影院-久久综合久久88-亚洲国产人成自久久国产-久久国产高清一区二区三区-自拍偷拍亚洲综合视频-精品久久久av免费观看

English

ENDPOINTSNEWS: On a quest to challenge Novo Nordisk in obesity, transpacific startup picks up $70M — and a pair of seasoned execs

2021-10-13

新聞截圖.png

— AUTHOR: Amber Tong, Senior Editor

— REPRINTED FROM ENDPOINTSNEWS

— ORIGINAL LINK: https://endpts.com/on-a-quest-to-challenge-novo-nordisk-in-obesity-transpacific-startup-picks-up-70m-and-a-pair-of-seasoned-execs/

Four years after starting Terns Pharmaceuticals together in search of an elusive NASH win, Weidong Zhong and Martijn Fenaux are reuniting at a new startup.

On paper, Sciwind Biosciences — which just raised $70 million in Series C cash — employs a similar setup as Terns: Both have embraced the transpacific model, taking root in China but planting flags in the US.

Zhong was tapped to be president of the San Francisco-based subsidiary back in July, on top of assuming the role as chief strategy officer. Weeks later, Fenaux has been appointed SVP, nonclinical development and translational science at the parent company out of Hangzhou — joining the team alongside chief scientific officer Xinle Wu, who brings experience running R&D for both Eli Lilly and Amgen in China.

Whereas Terns is focused on NASH and other liver diseases, Sciwind positions itself as a specialist in metabolic disorders. The three lead candidates all congregate around GLP-1 receptor agonism, a mechanism that Sciwind reckons is relevant across fatty liver, obesity and diabetes.

The new infusion marks Sciwind’s second financing in a year, having bagged $37 million in February to fuel the clinical work underway for XW003 (long-acting GLP-1 peptide analog) in type 2 diabetes and obesity. Topline Phase II data are expected in the second half of 2022.

To reach those massive markets, the biotech would first have to steer past giant rivals like Novo Nordisk, whose GLP-1 peptide analog semaglutide is already approved in the US for both of those indications.

Then there's the follow-on XW004, which is designed for once daily rather than once weekly administration, slated for first-in-human trials later this year; and XW014, a preclinical small molecule GLP-1R agonist.

But IDG Capital, Loyal Valley Capital and LYFE Capital have no trouble believing in Sciwind and founder/CEO Hai Pan, leading the latest round.

无码人妻啪啪一区二区 | 强行挺进美艳老师的后臀 | 96视频人澡人澡日日 | 亚洲精品无码成人AAA片 | 国产a一级毛片爽爽影院无码 | 国产在线一区观看 | 欧美日韩中文字幕群交视频在线观看 | 国模娜娜一区二区三区 | 日韩丰满少妇无码内射 | 亚洲综合AV色婷婷五月蜜臀 | 97久精品国产片一区二区三区 | 亚洲AV无码一区二区三区乱子伦 | 情浓野战台湾三级 | 国产精品99精品无码视亚 | 日本乱人伦aⅴ精品潮喷 | 日本老头老太XING交 | 黄色网址视频在线播放 | 国产午夜精品一区二区三区软件 | 特黄特色欧美亚洲高清二区 | 国产精品第1页在线观看 | 日韩精品久久久肉伦网站 | 久久中文字幕一区二区三区 | 国产精品看片在线观看 | 最近中文字幕完整视频大全 | 日韩一区二区免费视频 | 97亚洲熟妇自偷自拍另类图片 | 亚欧洲精品在线视频免费观看 | 中文字幕人乱码中文字幕 | 爆乳护士一区二区三区在线播放 | 亚洲成人一区二区 | 亚洲中文字幕精品久久app | 女网址www女视频 | 一级做a爰片久久免费 | 在线观看亚洲中文字幕 | 免费特黄一区二区三区视频一 | 秋葵视频ios无限制解码免费版下载 | 男人裸身露j不挡的图片 | 国产无套内射普通话对白 | 国产欧美一区二区三区久久 | 久久人人爽人人澡人人高潮av | 国产成+人+综合+欧美亚洲 |